Genetic Etiology for Alcohol-Induced Cardiac Toxicity

Background: Alcoholic cardiomyopathy (ACM) is defined by a dilated and impaired left ventricle due to chronic excess alcohol consumption. It is largely unknown which factors determine cardiac toxicity on exposure to alcohol.

Objectives: This study sought to evaluate the role of variation in cardiomyopathy-associated genes in the pathophysiology of ACM, and to examine the effects of alcohol intake and genotype on dilated cardiomyopathy (DCM) severity.

Methods: The authors characterized 141 ACM cases, 716 DCM cases, and 445 healthy volunteers. The authors compared the prevalence of rare, protein-altering variants in 9 genes associated with inherited DCM. They evaluated the effect of genotype and alcohol consumption on phenotype in DCM.

Results: Variants in well-characterized DCM-causing genes were more prevalent in patients with ACM than control subjects (13.5% vs. 2.9%; p = 1.2 ×10), but similar between patients with ACM and DCM (19.4%; p = 0.12) and with a predominant burden of titin truncating variants (TTNtv) (9.9%). Separately, we identified an interaction between TTN genotype and excess alcohol consumption in a cohort of DCM patients not meeting ACM criteria. On multivariate analysis, DCM patients with a TTNtv who consumed excess alcohol had an 8.7% absolute reduction in ejection fraction (95% confidence interval: -2.3% to -15.1%; p < 0.007) compared with those without TTNtv and excess alcohol consumption. The presence of TTNtv did not predict phenotype, outcome, or functional recovery on treatment in ACM patients.

Conclusions: TTNtv represent a prevalent genetic predisposition for ACM, and are also associated with a worse left ventricular ejection fraction in DCM patients who consume alcohol above recommended levels. Familial evaluation and genetic testing should be considered in patients presenting with ACM.

Citing Articles

Genome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypes.

Henry A, Mo X, Finan C, Chaffin M, Speed D, Issa H Nat Genet. 2025; .

PMID: 40038546 DOI: 10.1038/s41588-024-02064-3.

Genetic Background in Patients with Cancer Therapy-Induced Cardiomyopathy.

Fazzini L, Campana N, Cossu S, Deidda M, Madaudo C, Quagliariello V J Clin Med. 2025; 14(4).

PMID: 40004816 PMC: 11856774. DOI: 10.3390/jcm14041286.

Regulation of TTN as a mechanism of and treatment for heart failure.

Fullenkamp D J Clin Invest. 2025; 135(4).

PMID: 39959973 PMC: 11827840. DOI: 10.1172/JCI189335.

HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunction.

Dowsing B, Dehbi H, Chung R, Pedra J, Worn O, Artico J BMJ Open. 2025; 15(2):e091917.

PMID: 39909533 PMC: 11800297. DOI: 10.1136/bmjopen-2024-091917.

Regulation of sarcomere formation and function in the healthy heart requires a titin intronic enhancer.

Kim Y, Kim S, Saul D, Neyazi M, Schmid M, Wakimoto H J Clin Invest. 2024; 135(4).

PMID: 39688912 PMC: 11827849. DOI: 10.1172/JCI183353.

References

Ware J, Li J, Mazaika E, Yasso C, DeSouza T, Cappola T . Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med. 2016; 374(3):233-41. PMC: 4797319. DOI: 10.1056/NEJMoa1505517. View

Felkin L, Walsh R, Ware J, Yacoub M, Birks E, Barton P . Recovery of Cardiac Function in Cardiomyopathy Caused by Titin Truncation. JAMA Cardiol. 2016; 1(2):234-5. PMC: 6394809. DOI: 10.1001/jamacardio.2016.0208. View

Pua C, Bhalshankar J, Miao K, Walsh R, John S, Lim S . Development of a Comprehensive Sequencing Assay for Inherited Cardiac Condition Genes. J Cardiovasc Transl Res. 2016; 9(1):3-11. PMC: 4767849. DOI: 10.1007/s12265-016-9673-5. View

Jansweijer J, Nieuwhof K, Russo F, Hoorntje E, Jongbloed J, Lekanne Deprez R . Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. Eur J Heart Fail. 2016; 19(4):512-521. DOI: 10.1002/ejhf.673. View

Hershberger R, Hedges D, Morales A . Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013; 10(9):531-47. DOI: 10.1038/nrcardio.2013.105. View

Tayal U, Newsome S, Buchan R, Whiffin N, Halliday B, Lota A . Phenotype and Clinical Outcomes of Titin Cardiomyopathy. J Am Coll Cardiol. 2017; 70(18):2264-2274. PMC: 5666113. DOI: 10.1016/j.jacc.2017.08.063. View

Amor-Salamanca A, Guzzo-Merello G, Gonzalez-Lopez E, Dominguez F, Restrepo-Cordoba A, Cobo-Marcos M . Prognostic Impact and Predictors of Ejection Fraction Recovery in Patients With Alcoholic Cardiomyopathy. Rev Esp Cardiol (Engl Ed). 2018; 71(8):612-619. DOI: 10.1016/j.rec.2017.11.032. View

Fernandez-Sola J, Nicolas J, Oriola J, Sacanella E, Estruch R, Rubin E . Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. Ann Intern Med. 2002; 137(5 Part 1):321-6. DOI: 10.7326/0003-4819-137-5_part_1-200209030-00007. View

Fernandez-Sola J . Cardiovascular risks and benefits of moderate and heavy alcohol consumption. Nat Rev Cardiol. 2015; 12(10):576-87. DOI: 10.1038/nrcardio.2015.91. View

10.

Chami N, Tadros R, Lemarbre F, Lo K, Beaudoin M, Robb L . Nonsense mutations in BAG3 are associated with early-onset dilated cardiomyopathy in French Canadians. Can J Cardiol. 2014; 30(12):1655-61. DOI: 10.1016/j.cjca.2014.09.030. View

11.

Herman D, Lam L, Taylor M, Wang L, Teekakirikul P, Christodoulou D . Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012; 366(7):619-28. PMC: 3660031. DOI: 10.1056/NEJMoa1110186. View

12.

Tayal U, Prasad S, Cook S . Genetics and genomics of dilated cardiomyopathy and systolic heart failure. Genome Med. 2017; 9(1):20. PMC: 5322656. DOI: 10.1186/s13073-017-0410-8. View

13.

Walsh R, Thomson K, Ware J, Funke B, Woodley J, McGuire K . Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med. 2016; 19(2):192-203. PMC: 5116235. DOI: 10.1038/gim.2016.90. View

14.

Urbano-Marquez A, Estruch R, Navarro-Lopez F, Grau J, Mont L, Rubin E . The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med. 1989; 320(7):409-15. DOI: 10.1056/NEJM198902163200701. View

15.

Marinescu V, McCullough P . Nutritional and micronutrient determinants of idiopathic dilated cardiomyopathy: diagnostic and therapeutic implications. Expert Rev Cardiovasc Ther. 2011; 9(9):1161-70. DOI: 10.1586/erc.11.95. View

16.

. Alcohol and the heart in perspective. Sensible limits reaffirmed. A Working Group of the Royal Colleges of Physicians, Psychiatrists and General Practitioners. J R Coll Physicians Lond. 1995; 29(4):266-71. PMC: 5401333. View

17.

Schafer S, de Marvao A, Adami E, Fiedler L, Ng B, Khin E . Titin-truncating variants affect heart function in disease cohorts and the general population. Nat Genet. 2016; 49(1):46-53. PMC: 5201198. DOI: 10.1038/ng.3719. View

18.

Teragaki M, Takeuchi K, Toda I, Yoshiyama M, Akioka K, Tanaka M . Point mutations in mitochondrial DNA of patients with alcoholic cardiomyopathy. Heart Vessels. 2001; 15(4):172-5. DOI: 10.1007/pl00007268. View

19.

Whiffin N, Minikel E, Walsh R, ODonnell-Luria A, Karczewski K, Ing A . Using high-resolution variant frequencies to empower clinical genome interpretation. Genet Med. 2017; 19(10):1151-1158. PMC: 5563454. DOI: 10.1038/gim.2017.26. View

20.

George A, Figueredo V . Alcoholic cardiomyopathy: a review. J Card Fail. 2011; 17(10):844-9. DOI: 10.1016/j.cardfail.2011.05.008. View